Ascorbic Acid Shortage: A Provider Briefing for 2026

The ongoing supply disruption for injectable Ascorbic Acid continues to present challenges for prescribers across oncology, critical care, integrative medicine, and primary care settings. This briefing provides a comprehensive overview of the current situation, its clinical implications, and actionable steps for managing patients who require Vitamin C therapy.

Shortage Timeline: How We Got Here

The availability of injectable Ascorbic Acid in the United States has been unstable for over two decades:

• 1998-2017: Injectable Ascorbic Acid was widely available as an unapproved drug from multiple manufacturers and compounding pharmacies, but with no FDA-approved product on the market
• 2017: The FDA approved Ascor (Ascorbic Acid Injection, USP, 500 mg/mL) from McGuff Pharmaceuticals — the first and only FDA-approved injectable Ascorbic Acid
• 2019: The FDA issued notifications requesting companies cease distribution of unapproved Ascorbic Acid injection products, consolidating the market to a single manufacturer
• 2024: Supplemental FDA approval granted for Ascor (January 2024), potentially expanding labeled use and manufacturing flexibility
• 2025-2026: Ascor shipments placed on hold as McGuff coordinates with the FDA on remaining product release steps; supply remains intermittent

The ASHP Drug Shortages database continues to track this as an active shortage, with Mylan Institutional refusing to provide availability information for their products.

Prescribing Implications

The shortage affects several clinical scenarios:

Scurvy Treatment

Ascor's primary FDA-approved indication is the short-term (up to 1 week) treatment of scurvy in adult and pediatric patients aged 5 months and older when oral administration is not possible, insufficient, or contraindicated. For patients who can tolerate oral intake, switching to high-dose oral Ascorbic Acid (100-250 mg twice daily) remains effective for scurvy treatment.

High-Dose IV Vitamin C Therapy

Oncology practices using high-dose IV Ascorbic Acid as adjunctive therapy and critical care physicians who have incorporated it into sepsis protocols face the most significant impact. Without a reliable supply of Ascor, these protocols may need to be modified or paused.

Compounding Considerations

Under current FDA policy, compounding pharmacies face restrictions when preparing products for which an FDA-approved version exists. However, some 503B outsourcing facilities and 503A compounding pharmacies may still be able to prepare Ascorbic Acid injection under specific regulatory conditions. Prescribers should:

• Verify the regulatory status of any compounding source
• Confirm quality testing and sterility assurance protocols
• Document the clinical necessity for the compounded product

Current Availability Picture

As of early 2026:

• Ascor (McGuff): Shipments on hold; company states active coordination with FDA for release
• Generic injectable: No alternative FDA-approved injectable products available
• Compounded injectable: Limited availability through select outsourcing facilities; regulatory compliance varies
• Oral formulations: Widely available OTC — no shortage of tablets, capsules, powders, or liquid forms

Cost and Access Considerations

The financial picture for Ascorbic Acid varies significantly by formulation:

Injectable (Ascor)

• List price: approximately $5,690 for 1,250 mL (500 mg/mL concentration)
• Typically billed under medical benefit for inpatient/outpatient infusion
• Prior authorization frequently required
• Compounded alternatives may be less expensive but lack FDA approval

Oral Formulations

• Generic tablets (500 mg or 1000 mg): $4-$10 for 30-count supply
• Discount card pricing: as low as $4 for 30 tablets
• Generally not covered by insurance (OTC status) unless prescribed and purchased with FSA/HSA

For patients experiencing cost barriers with oral forms, Medfinder for Providers can help identify the most affordable pharmacy options in your patient's area.

Tools and Resources for Providers

Several resources can help you manage the impact of this shortage on your practice:

Medfinder for Providers

Medfinder allows you to check real-time pharmacy availability for Ascorbic Acid in your patient's area. This is particularly valuable when patients report difficulty filling prescriptions, saving both clinical and administrative time.

ASHP Drug Shortage Database

The ASHP maintains updated shortage information at ashp.org/drug-shortages, including manufacturer statements, estimated resupply dates, and therapeutic alternatives.

FDA Drug Shortages Database

The FDA's drug shortage database provides official status updates and any enforcement discretion decisions related to compounding during the shortage.

Patient Education Resources

Direct patients to the following resources for self-guided support:

• Ascorbic Acid shortage update for patients
• Alternatives to Ascorbic Acid
• Saving money on Ascorbic Acid

Looking Ahead

Several factors may influence the Ascorbic Acid supply outlook in the coming months:

• McGuff restoration: The manufacturer has publicly committed to returning Ascor to market; the timeline depends on FDA coordination
• Potential new entrants: No additional ANDA or NDA filings for injectable Ascorbic Acid have been publicly disclosed, but the shortage may incentivize development
• Compounding policy evolution: Congressional and regulatory discussions around compounding pharmacy authority continue, which could affect access to compounded alternatives
• Oral alternatives: For patients whose clinical scenario allows it, transitioning to oral Vitamin C supplementation eliminates the supply concern entirely

Final Thoughts

The Ascorbic Acid injection shortage is a single-manufacturer problem compounded by regulatory constraints and rising demand. While oral forms remain abundantly available, providers who depend on injectable Vitamin C for their clinical protocols face genuine access challenges.

Proactive supply monitoring, early patient communication, and readiness to adjust treatment plans are essential. Use Medfinder for Providers to track availability, and consider bookmarking the ASHP and FDA shortage databases for regular updates.

For a practical guide on helping patients navigate access challenges, see our companion article: How to Help Your Patients Find Ascorbic Acid in Stock.